Brain tumour treatment developer Extruded Pharmaceuticals reversed into Amur Minerals Corporation, which had sold its mining asset and become a shell, to form CRISM Therapeutics Corporation on 31 May. There was a one-for-160 share consolidation prior to the readmission.
The shell had cash in it, but it will not last long. Management believes that there is enough to start a phase II clinical trial for the ChemoSeed implantable, bioresorbable drug delivery platform.
The opening share price ...
You are unauthorized to view this page.